Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis ONLINE FIRST

Hussein N. Yassine, MD1; Qingru Feng, MSc1; Ida Azizkhanian, MSc1; Varun Rawat, PhD1; Katherine Castor, PhD2; Alfred N. Fonteh, PhD2; Michael G. Harrington, MB, ChB2; Ling Zheng, PhD3; Bruce R. Reed, PhD4; Charles DeCarli, MD4; William J. Jagust, MD5; Helena C. Chui, MD3
[+] Author Affiliations
1Division of Endocrinology, Department of Medicine, University of Southern California, Los Angeles
2Huntington Medical Research Institute, Pasadena, California
3Department of Neurology, University of Southern California, Los Angeles
4Department of Neurology, University of California Davis, Sacarmento
5Helen Wills Neuroscience Institute, University of California Berkeley
JAMA Neurol. Published online August 08, 2016. doi:10.1001/jamaneurol.2016.1924
Text Size: A A A
Published online

Importance  Higher dietary intake of the essential fatty acid docosahexaenoic (DHA) has been associated with better cognitive performance in several epidemiological studies. Animal and in vitro studies also indicate that DHA prevents amyloid deposition in the brain.

Objective  To determine the association between serum DHA levels, cerebral amyloidosis, and the volumes of brain areas affected by Alzheimer disease.

Design, Settings, and Participants  Cross-sectional analysis of serum DHA levels together with measures of amyloid deposition (Pittsburgh Compound B index), brain volumes, and neuropsychological testing scores from 61 participants in the Aging Brain Study. The study was conducted between June 2008 and May 2013, and the data were analyzed between October 2015 and April 2016. Linear models were adjusted for age, sex, years of education, and apolipoprotein E status.

Main Outcomes and Measures  Serum DHA levels with cerebral amyloidosis measured using PIB PET.

Results  Samples were available from 61 Aging Brain Study participants (41 women and 20 men) who underwent amyloid PET imaging. The mean (SD) age of the participants was 77 (6) years and ranged from 67 to 88 years. Serum DHA levels (percentage of total fatty acids) were 23% lower in participants with cerebral amyloidosis than those without (0.97 vs 1.25, P = .007) and were inversely correlated with brain amyloid load (r = −0.32, P = .01) independent of age, sex, apolipoprotein E genotype, and years of education. Moreover, greater serum DHA levels were positively associated with brain volume in several subregions affected by AD, in particular the left subiculum (r = 0.38, P = .005) and the left entorhinal volumes (r = 0.51, P = .001). Serum DHA levels were also associated with nonverbal memory scores (r = 0.28, P = .03).

Conclusions and Relevance  In this study, serum DHA levels were associated with pathogenesis of cerebral amyloidosis and with preservation of entorhinal and hippocampal volumes. These findings suggest an important role for DHA metabolism in brain amyloid deposition during the preclinical or early symptomatic stages of Alzheimer disease.

Figures in this Article


Place holder to copy figure label and caption
Figure 1.
Association of Docosahexaenoic Acid (DHA) Levels and Apolipoprotein E Genotype With Cerebral Amyloidosis

The relationship between cerebral amyloidosis as assessed by Pittsburgh compound B (PiB) positron emission tomography (PET) scan and serum levels of DHA. A, Box plot of PiB index units in patients with and without APOE ε4 allele. B, Cerebral amyloid load (as indexed by PiB index units) in participants grouped according to the quartiles of their serum DHA levels (percentage of total fatty acids). C, The association of serum DHA levels with PiB index by APOE genotype. Serum DHA explained 10% of the variability in cerebral amyloidosis (R2 = 0.1), whereas both serum DHA and APOE together explained 23% of cerebral amyloidosis (R2 = 0.23). The groups were compared by Wilcox on t test or analysis of variance. The relationship was modeled using a linear regression. Serum DHA units are the percentage of total fatty acids.

aP < .05.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Association of Serum Docosahexaenoic Acid (DHA) With Regional Brain Volumes Involved in Cognitive Functions

A, The correlation of hippocampal volume with serum DHA levels in 52 participants from the Aging Brain Study. Serum DHA (percentage of total fatty acids) was associated with hippocampal volume. Serum DHA explained 14% of the variability in hippocampal volumes (R2 = 0.14; P = .005). B, An association between serum DHA and left entorhinal volume was observed and explained 24% of the variability in hippocampal volume (R2 = 0.24; P < .001). The relationships were modeled using a linear regression. Brain volume is reported as a ratio of intracranial volume. Serum DHA units are reported as a percentage of total fatty acids.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles